Galena Biopharma Inc  

(Public, NASDAQ:GALE)   Watch this stock  
Find more results for GALE
1.61
-0.02 (-1.53%)
Real-time:   2:33PM EST
NASDAQ real-time data - Disclaimer
Currency in USD
Range 1.59 - 1.66
52 week 1.51 - 7.77
Open 1.63
Vol / Avg. 979,932.00/1.44M
Mkt cap 193.75M
P/E     -
Div/yield     -
EPS -0.70
Shares 121.46M
Beta 1.12
Inst. own 18%
Mar 16, 2015
Q4 2014 Galena Biopharma Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Feb 9, 2015
Galena Biopharma Inc at Biotechnology Industry Organization CEO & Investor Conference Add to calendar
Jan 19, 2015
Galena Biopharma Inc at Noble Financial Equity Conference Add to calendar
Dec 10, 2014
Galena Biopharma Inc at Oppenheimer Healthcare Conference
Nov 19, 2014
Galena Biopharma Inc at Stifel Healthcare Conference
Nov 3, 2014
Q3 2014 Galena Biopharma Inc Earnings Call
Nov 3, 2014
Q3 2014 Galena Biopharma Inc Earnings Release
Sep 25, 2014
Galena Biopharma Inc Announces Release of Special Committee Report and Provides Abstral� (fentanyl) and NeuVaxT (nelipepimut-S) Enrollment Updates
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin -381.05% -3083.15%
Operating margin -778.46% -1397.91%
EBITD margin - -1342.50%
Return on average assets -30.99% -107.27%
Return on average equity -83.69% -455.85%
Employees 60 -
CDP Score - -

Address

SUITE 270 4640 SW MACADAM AVENUE
PORTLAND, OR 97239
United States - Map
+1-855-8554253 (Phone)
+1-302-6365454 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Galena Biopharma, Inc. (Galena) is a biopharmaceutical company. The Company is developing and commercializing oncology therapeutics that address medical needs across the spectrum of cancer care. Galena�s development portfolio ranges from mid- to late-stage clinical assets, including an immunotherapy program led by NeuVax (nelipepimut-S) was in an international, Phase III clinical trial as of December 8, 2014. The Company�s commercial drugs include Abstral (fentanyl) Sublingual Tablets and Zuplenz (ondansetron) Oral Soluble Film. Its other pipeline products include GALE-301 (Folate Binding Protein (FBP)) and GALE-401 (Anagrelide CR). GALE-301 is immunogenic and can stimulate cytotoxic T lymphocyte (CTLs) to recognize and destroy FBP-expressing cancer cells. GALE-401 contains the active ingredient anagrelide, the United States Food and Drug Administration FDA-approved product.

Officers and directors

Sanford J. Hillsberg J.D. Independent Chairman of the Board
Age: 65
Bio & Compensation  - Reuters
Mark W. Schwartz Ph.D. President, Chief Executive Officer
Age: 58
Bio & Compensation  - Reuters
Ryan M. Dunlap Chief Financial Officer, Vice President, Secretary
Age: 44
Bio & Compensation  - Reuters
Irving M. Einhorn Director
Age: 72
Bio & Compensation  - Reuters
William L. Ashton Independent Director
Age: 63
Bio & Compensation  - Reuters
Richard H. Chin M.D. Independent Director
Age: 47
Bio & Compensation  - Reuters
Stephen S. Galliker CPA Independent Director
Age: 67
Bio & Compensation  - Reuters
Steven A Kriegsman Independent Director
Age: 72
Bio & Compensation  - Reuters